Serotonin Control of Impulsivity in Tourette Disorder (ARITEP)

Involvement of the Serotonergic System in the Control of Impulsivity in Tourette Disorder.

Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A receptors may play an important role in regulating psychiatric symptoms in TD such as those characterized by impulsive behaviors. To investigate the involvement of 5-HT2A receptors in TD, we propose to perform a multimodal imaging study with 20 adult patients (ON and OFF treatment). Neuroimaging data will be collected with a hybrid system that simultaneously combines the positron emission tomography (PET) and the functional magnetic resonance imaging (fMRI). A highly selective PET radiotracer ([18F]-altanserin) will map 5-HT2A receptor bindings in the whole brain, while fMRI will provide detail information regarding the altered brain activities.

Study Overview

• Status: Recruiting
• Conditions: Tourette Disorder
• Intervention / Treatment: Drug: Administration of a PET radiotracer

• Study Type: Interventional
• Enrollment (Estimated): 25
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Benjamin PASQUEREAU; Phone Number: +33 437 911 241; Email: benjamin.pasquereau@isc.cnrs.fr
• Study Contact Backup: Name: Stephane THOBOIS; Phone Number: +33 472 357 222; Email: stephane.thobois@chu-lyon.fr

Study Locations

• France
  • Bron, France, 69677
    • Recruiting
    • Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon
    • Contact: Stephane THOBOIS, MD
  • Paris, France, 75013
    • Not yet recruiting
    • Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière
    • Contact: Yulia WORBE, MD; Phone Number: +33 142 161 316; Email: yworbe@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

• Inclusion Criteria * :

  • Male or Female
  • Diagnosed with a Tourette Disorder following the DSM-5
  • Age between 18-65 years
  • Member of a social security scheme in France
  • Freely-given informed consent to participate to this study (written form)
  • With a current treatment by aripiprazole already scheduled
  • With Tics compatible with TEP/fMRI exams
  • Having (for women only) effective contraception throughout participation in the study.

Exclusion Criteria * :

• Male or Female
• A serious not controlled psychiatric comorbidity
• A serious, evolving or debilitating pathology with a potential influence on the study
• Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
• Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
• Women breastfeeding
• Protected or restricted person (administratively or in judicial terms)
• Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study
• Do not speak french

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Tourette disorder; 25 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.

Drug: Administration of a PET radiotracer; A highly selective 5-HT2A receptor ligand ([18F]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine. Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11).	Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.	As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation coefficients between receptor-specific imaging data (PET) and other clinical/behavioral scores.	Correlation coefficients between changes in the binding potential (BPND) of [18F]-altanserin measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.	As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Correlation coefficients between functional imaging data (fMRI) and scores of impulsivity measured by the Barratt scale (BIS11).	Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.	As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Correlation coefficients between functional imaging data (fMRI) and other clinical/behavioral scores.	Correlation coefficients between changes in the BOLD signal measured voxel-by-voxel in the whole brain and the evolution of other clinical scores and task performance of TD patients.	As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon

Study record dates

Study Major Dates

• Study Start (Actual): September 24, 2024
• Primary Completion (Estimated): September 24, 2027
• Study Completion (Estimated): September 24, 2028

Study Registration Dates

• First Submitted: July 4, 2023
• First Submitted That Met QC Criteria: July 4, 2023
• First Posted (Actual): July 12, 2023

Study Record Updates

• Last Update Posted (Estimated): December 4, 2024
• Last Update Submitted That Met QC Criteria: December 2, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Impulsivity; Serotonin; Neuroimaging; Tourette
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Genetic Diseases, Inborn; Neurodegenerative Diseases; Neurodevelopmental Disorders; Movement Disorders; Heredodegenerative Disorders, Nervous System; Basal Ganglia Diseases; Tic Disorders; Impulsive Behavior; Tourette Syndrome
• Other Study ID Numbers: 69HCL22_0683

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No